Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging study of ETVAX formulations
NCT05178134Phase 2Completed
- Sponsor
- Scandinavian Biopharma
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ETVAX in enterotoxigenic Escherichia coli infection (2 arms), sponsored by Scandinavian Biopharma. Primary endpoint: Response to vaccine (seroconversion of IgA/IgG anti-LTB) at 3 weeks. Started Nov 2021; status: completed.
02
Drugs
ETVAX
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT05178134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178134.